Select language:  
1800 620 420
Close menu

New Directions in Leukaemia Research (NDLR) Conference 2024 to foster breakthroughs in blood cancer treatment

Monday Mar 4, 2024

The Leukaemia Foundation is proud to announce its role as the host and sponsor of the prestigious New Directions in Leukaemia Research (NDLR) Conference 2024, taking place from March 4 to March 6, 2024, in Adelaide, Australia.

The NDLR Conference serves as a pivotal platform where top scientists and clinicians convene to explore emerging breakthroughs in leukaemia research and treatment. This year’s event aims to address complex challenges in the field of blood cancer, with a focus on discovering innovative therapies.

Under the distinguished co-chairmanship of Professor Deborah White and Associate Professor Daniel Thomas, the NDLR Conference will facilitate collaboration, innovation, and the exchange of cutting-edge discoveries. Both co-chairs bring with them extensive expertise and dedication to advancing the field of blood cancer research.

Mr Tim Murphy, General Manager of Blood Cancer Partnerships at the Leukaemia Foundation said, NDLR 2024 offers a unique opportunity for scientists and clinicians to come together and discuss the latest advancements in leukaemia research.

“Our goal is to harness the collective expertise of attendees to drive progress towards our vision of zero lives lost to blood cancer by 2035.”

The three-day event will feature presentations from renowned blood cancer clinicians and researchers, showcasing recent findings and fostering new collaborations. Attendees will have the opportunity to engage with experts in basic and translational research, as well as explore emerging therapies making an impact in clinical settings.

The Leukaemia Foundation’s National Research Program plays a pivotal role in supporting the work of researchers and clinicians across Australia, furthering the organisation’s mission to eradicate blood cancer.

With an unwavering commitment to funding research innovations driving rapid advancements in treatments, diagnostics, and novel therapies, the Leukaemia Foundation’s National Research Program has invested over $60 million over the past 24 years to propel groundbreaking discoveries and interventions across blood cancer.